Bayer receives global license to Compugen’s cancer immunotherapeutics
For the second time, Compugen Ltd. (Israeli drug discovery company that trades on Nasdaq) and Bayer HealthCare LLC are teaming up. This time, the Big Pharma is getting global rights to Compugen’s cancer antibodies targeting two immune checkpoint regulators that are critical in immunosuppression.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.